8 December 2015 - Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals, Inc. have announced that the U.S. FDA has approved Bendeka (bendamustine hydrochloride) injection, a new liquid, low volume (50 mL) formulation with a short (10 minute) infusion time.

For more details, go to: http://www.tevapharm.com/news/teva_pharmaceuticals_and_eagle_pharmaceuticals_announce_fda_approval_of_bendeka_bendamustine_hydrochloride_injection_12_15.aspx